X
Xueying Chen
Researcher at Novartis
Publications - 9
Citations - 567
Xueying Chen is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 421 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova,Lecia V. Sequist,Jose Manuel Perez Garcia,Fabrice Andre,Jean-Pierre Delord,Manuel Hidalgo,Jan H.M. Schellens,Philippe A. Cassier,D. Ross Camidge,Martin Schuler,Ulka Vaishampayan,Howard A. Burris,G. Gary Tian,M. Campone,Zev A. Wainberg,Wan-Teck Lim,Patricia LoRusso,Geoffrey I. Shapiro,Katie Parker,Xueying Chen,Somesh Choudhury,Francois Ringeisen,Diana Graus-Porta,Dale Porter,Randi Isaacs,Reinhard Buettner,Jürgen Wolf +26 more
TL;DR: BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
Journal ArticleDOI
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K. Pal,Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Raanan Berger,David I. Quinn,Matthew D. Galsky,Juergen Wolf,Christian Dittrich,Bhumsuk Keam,Jean Pierre Delord,Jan H.M. Schellens,Gwenaelle Gravis,J. Medioni,Pablo Maroto,Virote Sriuranpong,Chaiyut Charoentum,Howard A. Burris,Viktor Grünwald,Daniel P. Petrylak,Ulka N. Vaishampayan,Eliahu Gez,Ugo De Giorgi,Jae-Lyun Lee,Jens Voortman,Sumati Gupta,Sunil Sharma,Amir Mortazavi,David J. Vaughn,Randi Isaacs,Katie Parker,Xueying Chen,Kun Yu,Dale Porter,Diana Graus Porta,Dean F. Bajorin +34 more
TL;DR: BJJ398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease, highlighting putative mechanisms of resistance to the agent, which may be useful in following disease status.
Journal ArticleDOI
Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.
Sumanta K. Pal,Jonathan E. Rosenberg,Bhumsuk Keam,Juergen Wolf,Raanan Berger,Christian Dittrich,Jean H. Hoffman-Censits,David I. Quinn,Ruud van der Noll,Howard A. Burris,Matthew D. Galsky,Gwenaelle Gravis,Jae-Lyun Lee,Jacques Medioni,Amir Mortazavi,Pablo Maroto,Katie Parker,Xueying Chen,Randi Isaacs,Dean F. Bajorin +19 more
TL;DR: The FGFR3 alterations are frequent in UC and have a putative role in pathogenesis and progression, and an extended cohort of genetically selected pts were selected to further characterize BGJ398 activity in UC.
Journal ArticleDOI
A phase 1 study of IDH305 in patients with IDH1^R132-mutant acute myeloid leukemia or myelodysplastic syndrome
Courtney D. DiNardo,Andreas Hochhaus,Mark G. Frattini,Karen W.L. Yee,Thomas Zander,Alwin Krämer,Xueying Chen,Yan Ji,Nehal S. Parikh,Joungwoo Choi,Andrew H. Wei +10 more
TL;DR: The recommended dose for expansion/maximum tolerated dose of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) was identified and recommended phase 2 dose could not be declared.
Journal ArticleDOI
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss,Edwige Lorthiois,Louise Barys,Kim S. Beyer,Claudio Bomio-Confaglia,Heather E. Burks,Xueying Chen,Xiaoming Cui,Ruben de Kanter,Lekshmi Dharmarajan,Carmine Fedele,Marc Gerspacher,Daniel Guthy,Victoria Head,Ashley C. Jaeger,Eloísa Jiménez-Núñez,Jeffrey D. Kearns,Catherine Leblanc,Sauveur-Michel Maira,Jason Murphy,Helen Oakman,Nils Ostermann,Johannes Ottl,Pascal Rigollier,Danielle Roman,Christian Schnell,Richard Sedrani,Toshio Shimizu,Rowan Stringer,Andrea Vaupel,Hans Voshol,P. J. J. Wessels,Toni Widmer,Rainer Wilcken,Kun Xu,Frédéric Zecri,Anna F. Farago,Simona Cotesta,Saskia M. Brachmann +38 more
TL;DR: JDQ443 is a structurally unique, covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket and demonstrates selective antiproliferative activity in KRAS G 12C-mutated cell lines, including those with G12C/H95 double mutations.